Moderna receives $ 483 million BARDA award for development of COVID-19 vaccine


(Reuters) – Moderna Inc. said Thursday it had received a $ 483 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to accelerate the development of its candidate vaccine for the new coronavirus.

The experimental vaccine is currently being tested in an early stage trial by the United States National Institutes of Health and Moderna is expected to begin a mid-term trial in the second quarter.

Based on data from these studies and discussions with regulators, the company said an advanced study could start as early as fall 2020.

The drug developer said funding from BARDA would support the vaccine’s clinical development program, as well as the larger scale production of the candidate vaccine, mRNA-1273, in 2020.


Please enter your comment!
Please enter your name here